Although checkpoint antibody therapies can induce a response in basal-like breast cancer, tumor recurrence rates remain high because blockade therapies do not have sufficient immunotherapeutic strength and CD8 + T cells face exhaustion by tumor cells after infiltrating the tumor. This evidence concerns the gene CD8A and breast cancer.